TRAM-39

TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease[1][2][3][4].

Product Specifications

CAS Number

[197525-99-8]

UNSPSC

12352005

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tram-39.html

Purity

99.66

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N#CC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3Cl

Molecular Formula

C20H14ClN

Molecular Weight

303.78

References & Citations

[1]Davies PJ, et al. Different types of potassium channels underlie the long afterhyperpolarization in guinea-pig sympathetic and enteric neurons. Auton Neurosci. 2006 Jan 30;124 (1-2) :26-30.|[2]Burnham MP, et al. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br J Pharmacol. 2006 Jun;148 (4) :434-41.|[3]Ayabe T, et al. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem. 2002 Feb 1;277 (5) :3793-800.|[4]Wulff H, et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14 (13) :1437-57.